JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
- Conditions
- Cerebrovascular Accident
- Interventions
- Other: Acetylsalicylic Acid (ASA)
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1295
- Registration Number
- NCT00311402
- Locations
- ๐ฏ๐ต
9.178.062 Boehringer Ingelheim Investigational Site, Ako, Hyogo, Japan
๐ฏ๐ต9.178.097 Boehringer Ingelheim Investigational Site, Aoi-ku, Shizuoka, Shizuoka, Japan
๐ฏ๐ต9.178.074 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan
Case-Control Viramune (Nevirapine) Toxicogenomics Study
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 889
- Registration Number
- NCT00310843
- Locations
- ๐บ๐ธ
1100.1452.01003 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
๐บ๐ธ1100.1452.99999 Boehringer Ingelheim Investigational Site, Baltimore, Connecticut, United States
๐ฆ๐ท1100.1452.54002 Funcei, Capital Federal, Argentina
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 333
- Registration Number
- NCT00309608
- Locations
- ๐ซ๐ท
1218.6.3305A Euraxi Pharma, Joue les Tours, France
๐ธ๐ฐ1218.6.42105 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia
๐ธ๐ฐ1218.6.42104 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 296
- Registration Number
- NCT00297778
- Locations
- ๐ฆ๐น
248.596.43001 Boehringer Ingelheim Investigational Site, Innsbruck, Austria
๐ฆ๐น248.596.43005 Boehringer Ingelheim Investigational Site, Linz, Austria
๐ฆ๐น248.596.43003 Boehringer Ingelheim Investigational Site, Graz, Austria
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
- Conditions
- HIV Infections
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT00294372
- Locations
- ๐ฉ๐ช
Boehringer Ingelheim Investigational Site, Ulm, Germany
A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 157
- Registration Number
- NCT00292448
- Locations
- ๐ฏ๐ต
Boehringer Ingelheim Investigational Site, Yokote, Akita, Japan
Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)
- Conditions
- Venous Insufficiency
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 202
- Registration Number
- NCT00292435
- Locations
- ๐จ๐ฟ
Neurology-geriatric Institute, Moravsky Beroun, Czech Republic
๐ฆ๐นAKH Wien, Wien, Austria
๐ฆ๐นLKH Graz, Graz, Austria
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
- Conditions
- Thromboembolism
- Interventions
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2564
- Registration Number
- NCT00291330
- Locations
- ๐บ๐ธ
1160.53.01033 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States
๐บ๐ธ1160.53.01046 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States
๐บ๐ธ1160.53.01010 Boehringer Ingelheim Investigational Site, Marietta, Georgia, United States
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1354
- Registration Number
- NCT00281593
- Locations
- ๐บ๐ธ
1236.1.573 Boehringer Ingelheim Investigational Site, Long Beach, California, United States
๐บ๐ธ1236.1.560 Boehringer Ingelheim Investigational Site, Encinitas, California, United States
๐บ๐ธ1236.1.523 Boehringer Ingelheim Investigational Site, Buena Park, California, United States
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 76
- Registration Number
- NCT00281567
- Locations
- ๐ณ๐ฑ
Boehringer Ingelheim Investigational Site, Study chairs or principal investigators, Netherlands